Introduction
Over the past decade, Clostridium difficile has become a leading cause of nosocomial diarrhoea worldwide. This has been attributed, at least partly, to the emergence of hypervirulent C. difficile strains, such as ribotypes 027 and 078, which display increased resistance to a number of antibiotics and produce binary toxin in addition to toxin A and B (1). Infection caused by these strains has been associated with increased disease severity and mortality (2).
Cadazolid is a novel antibiotic which combines quinolone and oxazolidinone moieties into a new class of antibacterial agents referred to here as quinoxolidinones and is in clinical development for the treatment of C. difficile associated diarrhoea (CDAD), also known as C. difficile infection. In previous studies cadazolid showed potent in vitro activity against C. difficile clinical isolates (3-7), and in a human gut model of CDAD, while having only a very limited impact on bacteria of the normal gut microflora (7).
This current study was undertaken to determine the in vitro time-kill kinetic activity and postantibiotic effect (PAE) of cadazolid in comparison to fidaxomicin and vancomycin against a panel of 4 C. difficile strains, representing isolates from ribotypes 027, 078, 087 and 001.
References
1. Martin JSH, et al. Nature Reviews Gastroenterology & Hepatology 2016;13:2016-16.
2. Rupnik M, et al. Nature Reviews Microbiology 2009;7:526-36.
3. Locher HH, et al. Antimicrob Agents Chemother 2014; 58:901-8.
4. Locher HH, et al. Antimicrob Agents Chemother 2014; 58: 892-900.
5. Rashid MU, et al. Anaerobe 2013; 20: 32-35.
6. Hecht DW, et al. Abstract/poster E-808 of the 52nd Interscience Conference on Antimicrobial Agents and Chemotherapy, 2012, San Francisco, American Society for
Microbiology, Washington, DC, USA.
7. Chilton CH, et al. J Antimicrob Chemother 2014; 69:697-705.
1 Evotec (UK) Ltd, Manchester, United Kingdom
2 Actelion Pharmaceuticals Ltd, Gewerbestrasse 16, 4123 Allschwil, Switzerland
